DCM
CPRX

Delpha Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Delpha Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,938
Closed -$11K – 355
2017
Q4 		$11K Buy
+2,938
New +$9.71K 0.01% 1022

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Delpha Capital Management's CPRX Position: Q1 2018 in Review

Delpha Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2018, closing a stake of 2,938 shares — an estimated $11K sold.

Delpha Capital Management first reported a position in CPRX in Q4 2017 and held it in 1 quarter. The position peaked at $11K in Q4 2017. 98 funds tracked by Wall St. Rank hold CPRX as of Q1 2018.

  • Delpha Capital Management reported no remaining Catalyst Pharmaceutical position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 2,938 Catalyst Pharmaceutical shares in Q1 2018, an estimated $11K.
  • Delpha Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Catalyst Pharmaceutical position peaked at $11K in Q4 2017.
  • 98 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.